🇺🇸 FDA
Patent

US 9439979

Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction

granted A61KA61K31/522A61K45/06

Quick answer

US patent 9439979 (Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/522, A61K45/06, A61K48/0008, A61K48/005